Figure 7.

miR-146a treatment reduces inflammatory response via regulating target gene expression. miR-146a target PCR array shows highly differentially downregulated putative target genes of miR-146a in the sciatic nerves (A) and monocytes (B) in db/db mice treated with miR-146a or control (con) miRNA mimics. In silico TargetScan-predicted complementarity between miR-146a and 3′-untranslated regions (UTR) of predicted target genes including IRAK1, TRAF6, and ADAMTS3 is shown in C. Real-time RT-PCR validated the downregulated putative target genes of miR-146a detected by miR-146a target PCR array in the sciatic nerves (D) and monocytes (E) isolated from db/db mice treated with miR-146a or control cel–miR-67 mimics (10 mg/kg) at 24 h after the last treatment. F: Western blot analysis of target genes IRAK1 and TRAF6 and downstream NF-κB signaling as well as a new potential target gene, ADAMTS3, of miR-146a (10 mg/kg) in sciatic nerves harvested from db/db mice treated with miR-146a mimics or cel–miR-67 mimics and from nondiabetic mice (db/m) at 24 h after the last treatment. *P < 0.05 and #P < 0.05 compared with diabetic db/db mice treated with control cel–miR-67.